- U.S. commercial launch underway following U.S. FDA approval of LIVMARLI™ (maralixibat) oral solution
- Six-year analysis showing significant improvement in event-free survival with LIVMARLI compared to natural history cohort (p
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
On 6ix: 6ix.com/news/mirum-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides
Mirum Pharmaceuticals, Inc. on 6ix
Story so far
Earlier from Mirum Pharmaceuticals
- Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
- The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
- New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
- U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
- Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
Later from Mirum Pharmaceuticals
- Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
- Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
- LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021
- Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
- Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
Follow Mirum Pharmaceuticals into a list and get an email when it puts out news.
Follow Mirum Pharmaceuticals